Active substance
Cefaclor
- SFDA 34
- US FDA 33
- US price lines 2
- NHS prices 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BIOCEF 500MG CAPSULE | 500 mg | Capsule · Oral use | 15 Blister | SAR 48.10 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| CECLOR 125MG-5ML SUSP | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 20.85 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CECLOR 250 MG-5ML SUSP | 50 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 41.65 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CECLOR 250MG CAPSULE | 250 mg | Capsule · Oral use | 15 Blister | SAR 32.30 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CECLOR 500MG CAPSULE | 500 mg | Capsule · Oral use | 15 Blister | SAR 59.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CECLOR MR 375 MG TAB | 375 mg | Modified-release film-coated tablet · Oral use | 10 Blister | SAR 35.60 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CECLOR MR 500MG TAB | 500 mg | Modified-release film-coated tablet · Oral use | 10 Blister | SAR 42.85 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CECLOR MR 750 MG TAB | 750 mg | Modified-release film-coated tablet · Oral use | 10 Blister | SAR 52.30 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CLORACEF 250MG/5ML SUSP | 50 mg/ml | Suspension · Oral use | 1 Bottle | SAR 29.05 | Generic · Prescription | DAR ALDAWA | Valid |
| CLORACEF 375MG- 5ML SUSPENSION | 75 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 29.05 | Generic · Prescription | DAR ALDAWA | Valid |
| CLORACEF FORTE | 500 mg | Capsule · Oral use | 16 Blister | SAR 55.95 | NCE · Prescription | DAR ALDAWA | Valid |
| FORTICEF 500MG CAPSULES | 500 mg | Capsule · Oral use | 15 Blister | SAR 35.75 | Generic · Prescription | Ram Pharmaceutical Industries | Valid |
| MEDACEF 250MG CAPSULES | 250 mg | Capsule, hard · Oral use | 20 Blister | SAR 28.20 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Valid |
| MEDACEF 500MG CAPSULES | 500 mg | Capsule, hard · Oral use | 20 Blister | SAR 48.95 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Valid |
| TABICLOR 125MG-5ML SUSP | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 18.75 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TABICLOR 250MG-5ML SUSP | 50 mg | Powder for oral suspension · Oral use | 1 Bottle | SAR 34.00 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TABICLOR 375 MG- 5ML ORAL SUSPNSION | 75 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 32.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TABICLOR 500MG CAPS | 500 mg | Capsule, hard · Oral use | 15 Blister | SAR 53.45 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TABICLOR MR 750MG F.C TAB | 750 mg | Modified-release film-coated tablet · Oral use | 10 Blister | SAR 44.50 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| BIOCEF 125MG-5ML SUSPENSION | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 16.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
| BIOCEF 250MG CAPSULE | 250 mg | Capsule · Oral use | 15 Blister | SAR 26.15 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
| BIOCEF 250MG-5ML SUSPENSION | 50 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 30.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
| CLORACEF | 250 mg | Capsule · Oral use | 1 Blister | SAR 18.15 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
| CLORACEF | 50 mg/ml | Suspension · Oral use | 16 Bottle | SAR 31.00 | NCE · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
| FORTICEF 125MG-5ML POWDER FOR ORAL SUSP | 25 mg/ml | Powder for suspension · Oral use | 1 Bottle | SAR 13.20 | Generic · Prescription | Ram Pharmaceutical Industries | Withdrawn by MAH · Not Marketed |
9 more — full table
Indications — CHI Daman Drug Formulary
INTRA-ABDOMINAL INFECTIONS; RECURRENT URINARY TRACT INFECTIONS (UTI)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CEFACLOR | EQ 375MG BASE; EQ 500MG BASE | tablet, extended release · oral | TEVA | Prescription | 4 Sep 2002 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | YUNG SHIN PHARM | Prescription | 22 Jan 2004 |
| CEFACLOR | EQ 125MG BASE/5ML; EQ 187MG BASE/5ML; EQ 250MG BASE/5ML; EQ 375MG BASE/5ML | for suspension · oral | YUNG SHIN PHARM | Prescription | 17 Feb 2012 |
| CECLOR | EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | LILLY | Discontinued | 4 Apr 1979 |
| CECLOR | EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | for suspension · oral | LILLY | Discontinued | 4 Apr 1979 |
| CEFACLOR | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML; EQ 187MG BASE/5ML; EQ 375MG BASE/5ML | for suspension · oral | FACTA FARMA | Discontinued | 23 Apr 1979 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | CEPH INTL | Discontinued | 28 Jul 1979 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | IVAX SUB TEVA PHARMS | Discontinued | 27 Apr 1995 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | DAVA PHARMS INC | Discontinued | 27 Apr 1995 |
| CEFACLOR | EQ 375MG BASE/5ML | for suspension · oral | IVAX SUB TEVA PHARMS | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 250MG BASE/5ML | for suspension · oral | IVAX SUB TEVA PHARMS | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 187MG BASE/5ML | for suspension · oral | IVAX SUB TEVA PHARMS | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 125MG BASE/5ML | for suspension · oral | IVAX SUB TEVA PHARMS | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 375MG BASE/5ML | for suspension · oral | DAVA PHARMS INC | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 125MG BASE/5ML | for suspension · oral | DAVA PHARMS INC | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 187MG BASE/5ML | for suspension · oral | DAVA PHARMS INC | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 250MG BASE/5ML | for suspension · oral | DAVA PHARMS INC | Discontinued | 28 Apr 1995 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | CHARTWELL RX | Discontinued | 23 May 1996 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | TEVA | Discontinued | 24 Jun 1996 |
| CECLOR CD | EQ 375MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, extended release · oral | LILLY | Discontinued | 28 Jun 1996 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | TEVA | Discontinued | 16 Sep 1996 |
| CEFACLOR | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | RANBAXY | Discontinued | 28 Aug 1997 |
| CEFACLOR | EQ 375MG BASE/5ML | for suspension · oral | RANBAXY | Discontinued | 2 Oct 1997 |
| CEFACLOR | EQ 250MG BASE/5ML | for suspension · oral | RANBAXY | Discontinued | 2 Oct 1997 |
| CEFACLOR | EQ 187MG BASE/5ML | for suspension · oral | RANBAXY | Discontinued | 2 Oct 1997 |
8 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CEFACLOR 250 MG CAPSULE | $0.93233 | per EA | 23 Sep 2026 |
| US NADAC | CEFACLOR 500 MG CAPSULE | $1.09972 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Cefaclor 125mg/5ml oral suspension | £4.13 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Cefaclor 250mg/5ml oral suspension | £8.26 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Cefaclor 375mg modified-release tablets | £9.10 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cefaclor 500mg capsules | £7.50 | 21 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.